Loading patent…
AssigneesTransimmune AG, Yale University
InventorsRichard EDELSON, Olga SOBOLEV, Douglas HANLON, Aaron VASSAL, Kazuki TATSUNO, Patrick HAN
Estimating the term…
The present invention relates to methods for reducing or eliminating reactive T cells from a transplant or a part thereof prior to transplantation. The present invention also relates to methods for reducing immunogenicity in a transplant or a part thereof prior to transplantation. The present invention further relates to transplants obtained by the described methods and apoptotic agent treated transplants for use in reducing or preventing inflammatory conditions such as graft-versus-host disease. Specifically, the methods can be used to reduce graft versus host disease following transplantation.
A method to selectively reduce immunogenicity in a transplant or a part thereof prior to transplantation, the method comprising the following steps:
A method to selectively reduce immunogenicity in a transplant or a part thereof prior to transplantation, the method comprising the following steps:
The method according to any of the preceding claims, wherein the transplant or part thereof of step a) is derived from stem cells, bone marrow, peripheral blood, white blood cells, leukocytes or umbilical cord blood.
The method according to any of the preceding claims, wherein the transplant or part thereof of step a) comprises T-cells.
The method according to any of the preceding claims, wherein the transplant or part thereof of step a) is an allogeneic or haploidentical transplant.
The method according to any of the preceding claims, wherein the tissue sample of step b) is derived from blood and/or spleen of the recipient.
The method according to any of the preceding claims, wherein the cells capable of presenting antigens from the recipient of step b) are antigen presenting cells.
The method according to any of the preceding claims, wherein the at least one apoptotic agent of step d) or step e) is the combination of a psoralen and UVA, riboflavin-phosphate and UVA and/or 5-aminolevulinic acid and light.
The method according to any of the preceding claims, wherein the recipient's immune system has not been treated with radiation or chemotherapy before the transplantation.
The method according to any of the preceding claims, wherein the donor and/or recipient are mammalian, preferably human.
A method to selectively reduce immunogenicity in a transplant or a part thereof prior to transplantation, the method comprising the following steps:
The method according to any of the preceding claims, wherein the immunoreactivity caused by the transplant or part thereof is reduced.
A composition comprising:
Dependencies are inferred from the claim text.